QUIDELORTHO CORP (QDEL)
Health Care · In vitro diagnostics (IVD) · NASDAQ
Global diagnostics company providing immunoassay, molecular testing, clinical chemistry, and transfusion medicine solutions across labs, point-of-care, and molecular platforms.
What QUIDELORTHO CORP does
QuidelOrtho Corporation is a global in vitro diagnostics company that provides a broad portfolio of testing solutions including clinical chemistry, immunoassay, molecular diagnostics, point-of-care testing, and transfusion medicine products. The company operates across more than 140 countries through direct sales and distributor networks, serving hospitals, clinical laboratories, physician offices, blood banks, and retail clinics. Its products range from laboratory instruments and tests to rapid point-of-care diagnostics and donor screening assays. The company is undergoing a wind-down of its U.S. donor screening portfolio as of early 2026.
Themes: ["Clinical diagnostics","Immunoassay testing","Molecular diagnostics / infectious disease","Point-of-care diagnostics","Transfusion medicine / blood screening","Laboratory automation"]
Fundamentals
- Price$17.44 as of 2026-07-09 close
- Market cap$1.2B as of 2026-07-10
- 1-year return-44.8% as of 2026-07-09 close
- Net margin-45.6% as of 2026-07-10
- Gross margin+45.0% as of 2026-07-10
- ROE-56.3% as of 2026-07-10
- Debt / equity1.45 as of 2026-07-10
- Revenue growth (YoY)-3.9% as of 2026-07-10
- Revenue CAGR (3y)+17.1% SEC XBRL
- Beta0.69 as of 2026-07-10
Key risks (from latest filing)
["Significant debt burden ($2.5B long-term borrowings as of Q1 2026) and negative operating cash flow, with the company reporting a $91.8M net loss in Q1 2026 and unprofitable operations.","Declining revenue (-3.89% YoY) driven in part by the wind-down of the U.S. donor screening portfolio, compressing margins.","Exposure to competitive pressure in the diagnostics market from larger, diversified healthcare companies with greater resources and established market positions."]
Competitors & peers
- Roche Diagnostics
- Abbott Diagnostics
- Siemens Healthineers
- Becton Dickinson (BD)
- Bio-Rad Laboratories
- Grifols
- Ortho Clinical Diagnostics (pre-acquisition)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.